Featured Research

from universities, journals, and other organizations

High response rates seen in phase-III trial of chemotherapy, new drug and stem cells in myeloma

Date:
October 18, 2010
Source:
European Society for Medical Oncology
Summary:
The first study of its kind comparing two different approaches to treating newly diagnosed multiple myeloma has found that both treatments achieved a positive response, researchers say.

The first study of its kind comparing two different approaches to treating newly diagnosed multiple myeloma has found that both treatments achieved a positive response, researchers said at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

Dr Antonio Palumbo from Azienda Ospedaliera Universitaria San Giovanni Battista of Torino in Italy and colleagues tested the two approaches for using the drug in a Phase-III trial of 402 patients with newly diagnosed multiple myeloma.

All patients were first administered an induction regimen of the new drug lenalidomide with low-dose dexamethasone. Next they were randomly assigned to one of two consolidation treatments.

The first group of 202 patients received conventional treatment with a combination of melphalan and prednisone, plus lenalidomide. The second group of 200 were given high-dose melphalan plus autologous transplants of their own stem cells.

After the induction treatment, 83% of patients saw a partial response, meaning the level of paraprotein in their blood had dropped by half. Very good partial response (90% reduction in paraprotein) was seen in 34% of patients, and 6% saw a complete response, meaning there was no detectable paraprotein in their blood.

After the consolidation treatment with melphalan, prednisone and lenalidomide, the very good partial response rate was 56%, and the complete response rate was 14%. After high-dose melphalan plus stem cell transplant, very good partial responses were seen 52% of patients, and complete responses in 25%.

"We are actually pleased with these results, since both treatments improved the quality of response achieved with the induction regimen of lenalidomide and dexamethasone," said Dr Palumbo. "However we need a longer follow-up to assess the impact of this finding on both progression-free survival and overall survival."

"This is the first study that compares high-dose chemotherapy with hemopoietic stem-cell support against conventional-dose chemotherapy plus new drugs, and we are pleased to see that with the actual follow-up there was no difference in response between the two arms of the study."

Commented Professor Martin Dreyling, of Munich University Clinic: "Provided that a longer follow-up confirms the preliminary data on progression-free and overall survival, this ground-breaking study will potentially change the standard of care in younger patients with multiple myeloma. Thus, molecular targeted approaches may finally overcome the current approach based on high-dose chemotherapy and subsequent autologous transplantation."


Story Source:

The above story is based on materials provided by European Society for Medical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology. "High response rates seen in phase-III trial of chemotherapy, new drug and stem cells in myeloma." ScienceDaily. ScienceDaily, 18 October 2010. <www.sciencedaily.com/releases/2010/10/101012101841.htm>.
European Society for Medical Oncology. (2010, October 18). High response rates seen in phase-III trial of chemotherapy, new drug and stem cells in myeloma. ScienceDaily. Retrieved September 30, 2014 from www.sciencedaily.com/releases/2010/10/101012101841.htm
European Society for Medical Oncology. "High response rates seen in phase-III trial of chemotherapy, new drug and stem cells in myeloma." ScienceDaily. www.sciencedaily.com/releases/2010/10/101012101841.htm (accessed September 30, 2014).

Share This



More Health & Medicine News

Tuesday, September 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How 'Yes Means Yes' Defines Sexual Assault

How 'Yes Means Yes' Defines Sexual Assault

Newsy (Sep. 29, 2014) Aimed at reducing sexual assaults on college campuses, California has adopted a new law changing the standard of consent for sexual activity. Video provided by Newsy
Powered by NewsLook.com
Scientists May Have Found An Early Sign Of Pancreatic Cancer

Scientists May Have Found An Early Sign Of Pancreatic Cancer

Newsy (Sep. 29, 2014) Researchers looked at 1,500 blood samples and determined people who developed pancreatic cancer had more branched chain amino acids. Video provided by Newsy
Powered by NewsLook.com
Colo. Doctors See Cluster of Enterovirus Cases

Colo. Doctors See Cluster of Enterovirus Cases

AP (Sep. 29, 2014) Doctors at the Children's Hospital of Colorado say they have treated over 4,000 children with serious respiratory illnesses since August. Nine of the patients have shown distinct neurological symptoms, including limb weakness. (Sept. 29) Video provided by AP
Powered by NewsLook.com
Dr.'s Unsure of Cause of Fast-Spreading Virus

Dr.'s Unsure of Cause of Fast-Spreading Virus

AP (Sep. 29, 2014) Doctors at the Children's Hospital of Colorado say they have treated over 4,000 children with serious respiratory illnesses since August. Nine of the patients have shown distinct neurological symptoms, including limb weakness. (Sept. 29) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins